Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials.

Harman NL, James R, Wilding J, Williamson PR; SCORE-IT study team.

Trials. 2017 Dec 15;18(1):597. doi: 10.1186/s13063-017-2317-5. Review.

2.

Meglitinides increase the risk of hypoglycemia in diabetic patients with advanced chronic kidney disease: a nationwide, population-based study.

Wu PC, Wu VC, Lin CJ, Pan CF, Chen CY, Huang TM, Wu CH, Chen L, Wu CJ; NRPB Kidney Consortium.

Oncotarget. 2017 Apr 27;8(44):78086-78095. doi: 10.18632/oncotarget.17475. eCollection 2017 Sep 29.

3.

Monotherapy in Patients with Type 2 Diabetes Mellitus.

Rhee SY, Kim HJ, Ko SH, Hur KY, Kim NH, Moon MK, Park SO, Lee BW, Choi KM, Kim JH; Committee of Clinical Practice Guideline of Korean Diabetes Association.

Diabetes Metab J. 2017 Oct;41(5):349-356. doi: 10.4093/dmj.2017.41.5.349. Review.

4.

Monotherapy in patients with type 2 diabetes mellitus.

Rhee SY, Kim HJ, Ko SH, Hur KY, Kim NH, Moon MK, Park SO, Lee BW, Choi KM, Kim JH; Committee of Clinical Practice Guideline of Korean Diabetes Association.

Korean J Intern Med. 2017 Nov;32(6):959-966. doi: 10.3904/kjim.2017.312. Epub 2017 Oct 23. Review.

5.

Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.

Xu J, Rajaratnam R.

Cardiovasc Diabetol. 2017 Feb 2;16(1):18. doi: 10.1186/s12933-017-0499-5. Review.

6.
7.

Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action.

Lorenzati B, Zucco C, Miglietta S, Lamberti F, Bruno G.

Pharmaceuticals (Basel). 2010 Sep 15;3(9):3005-3020. Review.

8.

Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis.

Czech M, Rdzanek E, Pawęska J, Adamowicz-Sidor O, Niewada M, Jakubczyk M.

BMC Endocr Disord. 2015 Oct 12;15:57. doi: 10.1186/s12902-015-0052-z. Review.

9.

Increased Serum Insulin Exposure Does Not Affect Age or Stage of Pancreatic Adenocarcinoma Diagnosis in Patients With Diabetes Mellitus.

Chao DT, Shah NH, Zeh HJ 3rd, Bahary N, Whitcomb DC, Brand RE.

Pancreas. 2016 Feb;45(2):228-33. doi: 10.1097/MPA.0000000000000439.

10.
11.

Diabetes mellitus: new challenges and innovative therapies.

Sena CM, Bento CF, Pereira P, Seiça R.

EPMA J. 2010 Mar;1(1):138-63. doi: 10.1007/s13167-010-0010-9. Epub 2010 Mar 13.

12.

Updated review: improved glycemic control with repaglinide-metformin in fixed combination for patients with type 2 diabetes.

Richard JW 3rd, Raskin P.

Clin Med Insights Endocrinol Diabetes. 2011;4:29-37. doi: 10.4137/CMED.S5094. Epub 2011 Jun 7.

13.

Management of diabetes across the course of disease: minimizing obesity-associated complications.

Apovian CM.

Diabetes Metab Syndr Obes. 2011;4:353-69. doi: 10.2147/DMSO.S24022. Epub 2011 Oct 12.

14.
16.

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.

Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S.

Ann Intern Med. 2011 May 3;154(9):602-13. doi: 10.7326/0003-4819-154-9-201105030-00336. Epub 2011 Mar 14. Review. Erratum in: Ann Intern Med. 2011 Jul 5;155(1):67-8.

17.

Emerging treatment options for type 2 diabetes.

Piya MK, Tahrani AA, Barnett AH.

Br J Clin Pharmacol. 2010 Nov;70(5):631-44. doi: 10.1111/j.1365-2125.2010.03711.x. Review.

18.

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.

Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O, Parving HH, Vaag AA.

BMJ. 2009 Nov 9;339:b4324. doi: 10.1136/bmj.b4324.

19.

The role of surrogate endpoints in the evaluation of efficacy and safety of therapeutic interventions in diabetes mellitus.

Wieczorek A, Rys P, Skrzekowska-Baran I, Malecki M.

Rev Diabet Stud. 2008 Fall;5(3):128-35. doi: 10.1900/RDS.2008.5.128. Epub 2008 Nov 10.

20.

A review of nateglinide in the management of patients with type 2 diabetes.

Tentolouris N, Voulgari C, Katsilambros N.

Vasc Health Risk Manag. 2007;3(6):797-807. Review.

Supplemental Content

Support Center